Deep Learning of Resting-state Electroencephalogram Signals for 3-class Classification of Alzheimer’s Disease, Mild Cognitive Impairment and Healthy Ageing

Objective. This study aimed to produce a novel deep learning (DL) model for the classification of subjects with Alzheimer's disease (AD), mild cognitive impairment (MCI) subjects and healthy ageing (HA) subjects using resting-state scalp electroencephalogram (EEG) signals. Approach. The raw EEG data were pre-processed to remove unwanted artefacts and sources of noise. The data were then processed with the continuous wavelet transform, using the Morse mother wavelet, to create time-frequency graphs with a wavelet coefficient scale range of 0-600. The graphs were combined into tiled topographical maps governed by the 10-20 system orientation for scalp electrodes. The application of this processing pipeline was used on a data set of resting-state EEG samples from age-matched groups of 52 AD subjects (82.3 ± 4.7 years of age), 37 MCI subjects (78.4 ± 5.1 years of age) and 52 HA subjects (79.6 ± 6.0 years of age). This resulted in the formation of a data set of 16197 topographical images. This image data set was then split into training, validation and test images and used as input to an AlexNet DL model. This model was comprised of five hidden convolutional layers and optimised for various parameters such as learning rate, learning rate schedule, optimiser, and batch size. Main results. The performance was assessed by a tenfold cross-validation strategy, which produced an average accuracy result of 98.9 ± 0.4% for the three-class classification of AD vs MCI vs HA. The results showed minimal overfitting and bias between classes, further indicating the strength of the model produced. Significance. These results provide significant improvement for this classification task compared to previous studies in this field and suggest that DL could contribute to the diagnosis of AD from EEG recordings

Comparison of resting electroencephalogram coherence in patients with mild cognitive impairment and normal elderly subjects

Mild cognitive impairment (MCI) was a condition beginning before more serious deterioration, leading to Alzheimer’s dementia (AD). MCI detection was needed to determine the patient's therapeutic management. Analysis of electroencephalogram (EEG) coherence is one of the modalities for MCI detection. Therefore, this study investigated the inter and intra-hemispheric coherence over 16 EEG channels in the frequency range of 1-30 Hz. The simulation results showed that most of the electrode pair coherence in MCI patients have decreased compared to normal elderly subjects. In inter hemisphere coherence, significant differences (p<0.05) were found in the FP1-FP2 electrode pairs. Meanwhile, significant differences (p<0.05) were found in almost all pre-frontal area connectivity of the intra-hemisphere coherence pairs. The electrode pairs were FP2-F4, FP2-T4, FP1-F3, FP1-F7, FP1-C3, FP1-T3, FP1-P3, FP1-T5, FP1-O1, F3-O1, and T3-T5. The decreased coherence in MCI patients showed the disconnection of cortical connections as a result of the death of the neurons. Furthermore, the coherence value can be used as a multimodal feature in normal elderly subjects and MCI. It is hoped that current studies may be considered for early detection of Alzheimer’s in a larger population

Classification of Mild Cognitive Impairment with Deep Transfer Learning Approach using CWT based Scalogram Images

Mild Cognitive Impairment (MCI) is a condition that can occur as a person gets older, and faces problems like recognition, memory, and language skills. Early detection of MCI is crucial, as it can progress to more severe conditions like Alzheimer's disease. This study proposes a method to use Scalogram images, obtained by applying Continuous Wavelet Transform (CWT) to EEG signals and pre-trained models like ResNet50, VGG16, InceptionV3, Inception_ResNetV2 through transfer learning to classify MCI and Healthy Control (HC). Fine-tuning of the models is also used to improve the results, and various performance metrics are employed for classification. The study concludes that Inception_ResNetV2 transfer learning yielded good results, while ResNet50 and InceptionV3 transfer learning with fine-tuning resulted in higher accuracy using a low learning rate

Ensemble of classifiers based data fusion of EEG and MRI for diagnosis of neurodegenerative disorders

The prevalence of Alzheimer\u27s disease (AD), Parkinson\u27s disease (PD), and mild cognitive impairment (MCI) are rising at an alarming rate as the average age of the population increases, especially in developing nations. The efficacy of the new medical treatments critically depends on the ability to diagnose these diseases at the earliest stages. To facilitate the availability of early diagnosis in community hospitals, an accurate, inexpensive, and noninvasive diagnostic tool must be made available. As biomarkers, the event related potentials (ERP) of the electroencephalogram (EEG) - which has previously shown promise in automated diagnosis - in addition to volumetric magnetic resonance imaging (MRI), are relatively low cost and readily available tools that can be used as an automated diagnosis tool. 16-electrode EEG data were collected from 175 subjects afflicted with Alzheimer\u27s disease, Parkinson\u27s disease, mild cognitive impairment, as well as non-disease (normal control) subjects. T2 weighted MRI volumetric data were also collected from 161 of these subjects. Feature extraction methods were used to separate diagnostic information from the raw data. The EEG signals were decomposed using the discrete wavelet transform in order to isolate informative frequency bands. The MR images were processed through segmentation software to provide volumetric data of various brain regions in order to quantize potential brain tissue atrophy. Both of these data sources were utilized in a pattern recognition based classification algorithm to serve as a diagnostic tool for Alzheimer\u27s and Parkinson\u27s disease. Support vector machine and multilayer perceptron classifiers were used to create a classification algorithm trained with the EEG and MRI data. Extracted features were used to train individual classifiers, each learning a particular subset of the training data, whose decisions were combined using decision level fusion. Additionally, a severity analysis was performed to diagnose between various stages of AD as well as a cognitively normal state. The study found that EEG and MRI data hold complimentary information for the diagnosis of AD as well as PD. The use of both data types with a decision level fusion improves diagnostic accuracy over the diagnostic accuracy of each individual data source. In the case of AD only diagnosis, ERP data only provided a 78% diagnostic performance, MRI alone was 89% and ERP and MRI combined was 94%. For PD only diagnosis, ERP only performance was 67%, MRI only was 70%, and combined performance was 78%. MCI only diagnosis exhibited a similar effect with a 71% ERP performance, 82% MRI performance, and 85% combined performance. Diagnosis among three subject groups showed the same trend. For PD, AD, and normal diagnosis ERP only performance was 43%, MRI only was 66%, and combined performance was 71%. The severity analysis for mild AD, severe AD, and normal subjects showed the same combined effect

What Electrophysiology Tells Us About Alzheimer’s Disease::A Window into the Synchronization and Connectivity of Brain Neurons

Electrophysiology provides a real-time readout of neural functions and network capability in different brain states, on temporal (fractions of milliseconds) and spatial (micro, meso, and macro) scales unmet by other methodologies. However, current international guidelines do not endorse the use of electroencephalographic (EEG)/magnetoencephalographic (MEG) biomarkers in clinical trials performed in patients with Alzheimer’s disease (AD), despite a surge in recent validated evidence. This Position Paper of the ISTAART Electrophysiology Professional Interest Area endorses consolidated and translational electrophysiological techniques applied to both experimental animal models of AD and patients, to probe the effects of AD neuropathology (i.e., brain amyloidosis, tauopathy, and neurodegeneration) on neurophysiological mechanisms underpinning neural excitation/inhibition and neurotransmission as well as brain network dynamics, synchronization, and functional connectivity reflecting thalamocortical and cortico-cortical residual capacity. Converging evidence shows relationships between abnormalities in EEG/MEG markers and cognitive deficits in groups of AD patients at different disease stages. The supporting evidence for the application of electrophysiology in AD clinical research as well as drug discovery pathways warrants an international initiative to include the use of EEG/MEG biomarkers in the main multicentric projects planned in AD patients, to produce conclusive findings challenging the present regulatory requirements and guidelines for AD studies

AI and Non AI Assessments for Dementia

Current progress in the artificial intelligence domain has led to the development of various types of AI-powered dementia assessments, which can be employed to identify patients at the early stage of dementia. It can revolutionize the dementia care settings. It is essential that the medical community be aware of various AI assessments and choose them considering their degrees of validity, efficiency, practicality, reliability, and accuracy concerning the early identification of patients with dementia (PwD). On the other hand, AI developers should be informed about various non-AI assessments as well as recently developed AI assessments. Thus, this paper, which can be readable by both clinicians and AI engineers, fills the gap in the literature in explaining the existing solutions for the recognition of dementia to clinicians, as well as the techniques used and the most widespread dementia datasets to AI engineers. It follows a review of papers on AI and non-AI assessments for dementia to provide valuable information about various dementia assessments for both the AI and medical communities. The discussion and conclusion highlight the most prominent research directions and the maturity of existing solutions.Comment: 49 page

Decision-based data fusion of complementary features for the early diagnosis of Alzheimer\u27s disease

As the average life expectancy increases, particularly in developing countries, the prevalence of Alzheimer\u27s disease (AD), which is the most common form of dementia worldwide, has increased dramatically. As there is no cure to stop or reverse the effects of AD, the early diagnosis and detection is of utmost concern. Recent pharmacological advances have shown the ability to slow the progression of AD; however, the efficacy of these treatments is dependent on the ability to detect the disease at the earliest stage possible. Many patients are limited to small community clinics, by geographic and/or financial constraints. Making diagnosis possible at these clinics through an accurate, inexpensive, and noninvasive tool is of great interest. Many tools have been shown to be effective at the early diagnosis of AD. Three in particular are focused upon in this study: event-related potentials (ERPs) in electroencephalogram (EEG) recordings, magnetic resonance imaging (MRI), as well as positron emission tomography (PET). These biomarkers have been shown to contain diagnostically useful information regarding the development of AD in an individual. The combination of these biomarkers, if they provide complementary information, can boost overall diagnostic accuracy of an automated system. EEG data acquired from an auditory oddball paradigm, along with volumetric T2 weighted MRI data and PET imagery representative of metabolic glucose activity in the brain was collected from a cohort of 447 patients, along with other biomarkers and metrics relating to neurodegenerative disease. This study in particular focuses on AD versus control diagnostic ability from the cohort, in addition to AD severity analysis. An assortment of feature extraction methods were employed to extract diagnostically relevant information from raw data. EEG signals were decomposed into frequency bands of interest hrough the discrete wavelet transform (DWT). MRI images were reprocessed to provide volumetric representations of specific regions of interest in the cranium. The PET imagery was segmented into regions of interest representing glucose metabolic rates within the brain. Multi-layer perceptron neural networks were used as the base classifier for the augmented stacked generalization algorithm, creating three overall biomarker experts for AD diagnosis. The features extracted from each biomarker were used to train classifiers on various subsets of the cohort data; the decisions from these classifiers were then combined to achieve decision-based data fusion. This study found that EEG, MRI and PET data each hold complementary information for the diagnosis of AD. The use of all three in tandem provides greater diagnostic accuracy than using any single biomarker alone. The highest accuracy obtained through the EEG expert was 86.1 ±3.2%, with MRI and PET reaching 91.1 +3.2% and 91.2 ±3.9%, respectively. The maximum diagnostic accuracy of these systems averaged 95.0 ±3.1% when all three biomarkers were combined through the decision fusion algorithm described in this study. The severity analysis for AD showed similar results, with combination performance exceeding that of any biomarker expert alone

The Role of MEG in Unveiling Cognition

info:eu-repo/semantics/publishedVersio